EnteroMedics' Maestro "on track" despite FDA questions
This article was originally published in Clinica
Executive Summary
EnteroMedics has been hit by more potential problems with its Maestro neuromodulation-based weight-loss device – this time in the shape of questions from the US FDA in response to the firm’s premarket approval (PMA) application. The company’s share price fell 12% to a low of $1.07 during trading on 24 September, when the news was released, but ended up recovering to close down 2% at $1.18.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.